UPDATE 1-Allergan says revenue from aesthetics unit may double by 2025
Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox. The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox. Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc and Evolus Inc vie to wrest market share with rival treatments to Botox.
Source:: https://finance.yahoo.com/news/allergan-says-revenue-aesthetics-unit-153451238.html
